D-Sight is an early treatment for the leading cause of preventable blindness in the working-age population.
D-Sight has raised $2.4M in total funding. The most recent round was Seed. The last funding was announced in February 2026.
D-Sight's investors include Bio Angels Club, Clave Capital, ICF - Institut Català de Finances, Prous Institute for Biomedical Research.
D-Sight is headquartered in Barcelona, Spain.
D-Sight is an early treatment for the leading cause of preventable blindness in the working-age population.
D-Sight is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"D-Sight — Funding & Investors." VCBacked, February 23, 2026, https://www.vcbacked.co/company/d-sight. Accessed August 14, 2026.
VCBacked. (2026). D-Sight — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/d-sight
{{cite web |title=D-Sight — Funding & Investors |url=https://www.vcbacked.co/company/d-sight |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated